India’s cheap weight-loss drugs could reshape global obesity fight
Short excerpt below. Click through to read at the original source.
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
Short excerpt below. Click through to read at the original source.
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.